Latest Articles

Technology Networks invited Dr. Heifets, assistant professor at the Stanford School of Medicine, to an Ask Me Anything session to answer your questions about psychedelics.

Technology Networks invited chief editor at Nature Biotechnology, Barbara Cheifet, to an Ask Me Anything session to answer questions about the biggest challenges in scientific publishing and how to get work published in high-ranking journals.

Immune cells come in many shapes and sizes and with numerous different properties. In this article, we consider what eosinophils are, how they are generated, their function in the body and medical conditions related to them, including eosinophilia.

The impetus to demonstrate regulatory compliance to ensure their products are safe for human consumption is an imperative for pharmaceutical and biotechnology organizations.

Thanks to the rise of AI, HTS for drug discovery is taking a more intelligent, computational approach, with tools that allow scientists to pinpoint the most promising drug candidates faster. Explore how this evolution will be further enhanced by a shift from 2D to 3D biological models such as organoids.

An organ-on-a-chip is a model system containing engineered cells grown inside microfluidic chips. This article will highlight some recent advances in organ-on-a-chip technology and how they are being used to improve disease modeling and drug discovery.

Using data provided by Intercontinental Exchange, My Green Lab has produced a report providing key insights into the current state of the sector’s carbon emissions. James Connelly highlights some of the key findings and their significance.

This article explores several examples of how comprehensive modeling tools and expert guidance can help determine what specific adaptations can optimize trials.

The COVID-19 global pandemic has left in its wake a baffling array of symptoms, affecting many survivors for months after the virus has run its course. This article explores the current state of long COVID research.

Dr. Darrell Green's best friend, Ben, developed bone cancer and passed away just before his 14th birthday. This profile article explores how this experience stayed with Green, and has propelled his work towards a new treatment for bone cancer.